|
by Dale Kiefer
Scientists have discovered a
natural ingredient derived from a species of melon that has been
shown to reverse signs of atherosclerosis in aging blood vessel
walls. This nutritional supplement is able to boost levels of
the body’s most powerful antioxidant defense enzyme, superoxide
dismutase (SOD).
A comparison of two
recently-published clinical trials shows that this natural
supplement not only reversed signs of atherosclerosis in human
blood vessel walls, but that it did so better than a leading
multibillion dollar prescription statin drug. Just eight months
ago, Life Extension members were enlightened to the ability of
pomegranate to reverse signs of atherosclerosis. This
specialized melon extract, together with pomegranate, offers
aging humans a powerful new weapon in the battle to reduce the
risk of heart attack and stroke by restoring healthy function to
aging arteries.
Atherosclerosis: the Silent Enemy
Even people who have no symptoms
of cardiovascular disease may be developing silent, progressive
atherosclerosis as they grow older. Derived from Greek words
meaning “hard paste”, atherosclerosis is a chronic inflammatory
condition affecting the interior of the arteries, which become
stiff, clogged, and dysfunctional. Consisting of cholesterol,
cellular debris, and other components, atherosclerotic plaque
blocks the flow of vital oxygen and nutrients to tissues
throughout the body.
Atherosclerosis is believed to
begin when the delicate inner arterial lining—the endothelium—is
damaged and becomes dysfunctional; possibly beginning as early
as childhood.1
Sticky, fatty substances, such as low-density lipoprotein (LDL),
fibrinogen, and triglycerides adhere to the endothelial lining
and begin to trap other components, including calcium. The
plaque may cause a rupture in the arterial wall, allowing a
blood clot to form. Clots can block local blood flow completely,
or they may break free and cause dangerous blockages elsewhere.
When such blockages occur in the vessels supplying the heart,
for instance, a heart attack occurs. Deprived of oxygen, cardiac
muscle dies quickly; when a blockage affects the blood supply to
the brain, a stroke may result.
The Superoxide Radical and
Endothelial Dysfunction: Danger to Aging Arteries
Damage to cells that line our
arteries is a critical initiating event in atherosclerosis, a
leading cause of heart attack and stroke. As the delicate
endothelium (inner arterial wall) becomes weakened, toxic
substances circulating in the blood pass through the endothelial
cell layer and become oxidized. This oxidation induces chronic
inflammation that leads to thickening of the blood vessel wall
and subsequent atherosclerosis. Depending on a person’s
individual risk factors (such as poor diet, lack of exercise,
high homocysteine, high levels of inflammation, smoking, high
blood pressure, and the aging process itself), oxidized lipids
continue to accumulate in the endothelium, and the
atherosclerotic process accelerates.
Scientists know that oxidative
stress is a crucial, causal factor in endothelial dysfunction,
which itself is a key initiating event for abnormal blood vessel
wall thickening and atherosclerosis. Cutting-edge research shows
that superoxide dismutase, the body’s most important antioxidant
defense enzyme, plays an important role in maintaining healthy
endothelial function by quenching dangerous superoxide radicals.
The superoxide radical inactivates
the crucial vasodilator nitric oxide and compromises endothelial
function.2,3
Furthermore, rapid improvement in endothelial function and
regression of atherosclerosis is associated with reduction of
the dangerous superoxide radical in the arterial wall.4
New research shows that the superoxide radical plays a role in
hypertension associated with kidney disease, oxidative vascular
stress associated with accelerated atherosclerosis in diabetes,
and heart failure in humans.5-8
Statin Drugs and Atherosclerosis
In the past, numerous studies have
examined the effects of cholesterol-lowering statin drugs on
atherosclerosis using proven ultrasound technology that measures
for pathological thickening (intima-media thickness, or IMT) of
the aging blood vessel wall. Interestingly, most large statin
drug trials show only slowing of progression, rather than
regression of atherosclerosis, as measured with this
highly-respected technology.
For example, the 1998 REGRESS
study showed slowing of progression of atherosclerosis, but not
regression, with the statin drug pravastatin (Pravachol®).16
The 1995 KAPS study also showed that
pravastatin produced a significant
slowing of progression of atherosclerosis, but not regression.17
Although the ASTEROID study showed evidence of regression of
atherosclerosis in high-risk patients, this study used the very
potent statin drug, rosuvastatin (Crestor®).18
Another head-to-head comparative study (ARBITER) showed slight
regression of IMT with a high dose of the potent drug
atorvastatin (Lipitor®).19
However, many “in the know” unbiased medical experts have raised
questions about the results of this study, commenting on data
handling and methodological issues used by the Pfizer-sponsored
investigators.
Recently, a clinical trial
published in the influential Journal of the American Medical
Association indicated that the cholesterol-lowering statin drug,
Crestor® (rosuvastatin), is capable of slowing the progression
of silent subclinical atherosclerosis. As expected, over the
course of two years, a high dose (40 mg) of the very potent
statin drug Crestor® significantly lowered harmful lipid levels.
But it merely slowed or halted atherosclerosis progression—it
did not produce regression. In the investigators’ own words: “Rosuvastatin
[Crestor®] did not induce disease regression.”20
In sharp contrast, a nutritional
supplement derived from a unique species of melon was shown
recently to not only halt IMT progression in apparently healthy
adults, but to significantly reverse its progression over the
course of two years.21
Conventional Approaches to Atherosclerosis
|
|
A variety of genetic and
environmental factors play key roles in the development of
atherosclerosis, but the understanding of this complex
process is still evolving in mainstream medicine. There’s no
question, however, about a number of all-too-common risk
factors. These include: obesity, inactivity, diabetes, high
blood pressure, insulin resistance, high lipid levels, low
HDL, elevated C-reactive protein, smoking, and a family
history of heart disease.
Mainstream medicine is just
beginning to recognize atherosclerosis-associated chronic
inflammation, perpetuated by oxidative stress and detectable
by biochemical markers that indicate ongoing inflammation
and oxidative damage.9,10
Age alone is a major risk
factor for atherosclerosis.11
This should come as no surprise, since aging is associated
with increasing inflammation, and inflammation is associated
with atherosclerosis development.12-14
Efforts to fight inflammatory and oxidative processes have
been shown to reverse some of the early damage that sets the
stage for atherosclerosis. Life Extension advocates a
comprehensive approach to averting cardiovascular disease
that includes addressing the many implicated triggers of
endothelial dysfunction and atherosclerosis, such as high
homocysteine, low levels of omega-3 fatty acids, and
elevated fibrinogen levels.15
Current mainstream medical
treatments for atherosclerosis generally focus on
controlling only a few of the multiple identified causes of
atherosclerosis. Life Extension advocates that members
aggressively monitor and treat ALL the known causes of
endothelial dysfunction and atherosclerosis as part of a
comprehensive strategy to minimize the risk of developing
our nation’s number one killer, cardiovascular disease.
|
Oral SOD Reverses IMT
Impressive new research indicates
that a patented form of the natural antioxidant superoxide
dismutase (SOD) significantly reverses the IMT thickening
process, long before atherosclerosis becomes life-threatening.21
Known as the “enzyme of life” when it was first discovered in
the late 1960s, SOD is considered the body’s most important
antioxidant defense enzyme. Its powerful benefits include the
ability to activate and regenerate other key native
antioxidants, such as glutathione peroxidase and catalase. By
itself, SOD disarms the extraordinarily reactive superoxide
radical. It accomplishes this feat with lightning speed, thus
preventing superoxide from wreaking havoc with important
biological tissues, including the delicate vascular endothelium.
Scientists have long sought a way
to boost levels of SOD as a natural means of combating the
oxidative damage that lies at the root of so many degenerative
disease processes, including atherosclerosis.21
Noting that certain varieties of cantaloupe had an exceptionly
long shelf life, food scientists found that these melons
provided an exceptionally rich source of SOD. Still, this SOD
remained stubbornly unavailable to the body when consumed
orally. Until, that is, French researchers pioneered a method to
“cloak” a natural melon-derived SOD molecule with gliadin (a
simple protein derived from wheat), protecting it from the harsh
acidic environment of the stomach and intestines long enough for
the bioactive SOD enzyme to be absorbed intact into the
bloodstream.22,23
Dubbed
GliSODin®, this compound has been thoroughly documented to be a
particularly potent orally bioavailable form of SOD. Many
competing products purporting to contain SOD are simply
ineffective. Without the protection of the gliadin molecule,
most SOD supplements are destroyed by the digestive tract long
before they can benefit the body, rendering them ineffective as
oral supplements.
Clinical Study Confirms Efficacy
of GliSODin® for Regression of Atherosclerosis
In a groundbreaking new study,
investigators led by Professor Maurice Cloarec from the French
National Association for Medical Prevention showed that oral
supplementation with GliSODin® was associated with regression of
atherosclerosis in middle-aged adults (ages 30-60), as
determined by ultrasonography. This finding is especially
exciting, in that atherosclerosis progression was not slowed,
nor halted, but rather that it was actually reversed.
The scientists began this study by
recruiting adults with risk factors for atherosclerosis,
including a family history of stroke, elevated blood pressure,
elevated blood lipids and blood sugar, and a height-to-weight
ratio above normal. Subjects received instruction in following a
standardized, heart-healthy, Mediterranean-type diet, and were
given counseling regarding lifestyle modifications.
A baseline IMT reading was
performed, and assessments were also made of individuals’
antioxidant status and blood lipid levels, among other health
parameters. All subjects first adhered to a new, healthier diet
for one year. At the end of the first year, the scientists
documented “minor improvements” in blood pressure, body mass
index (BMI), and LDL levels among all subjects. These
improvements were attributed to the healthier diet and lifestyle
modifications. Subjects’ antioxidant status, however, remained
poor. Furthermore, subjects’ IMT values remained unchanged.
Investigators noted that the IMT numbers were, “too
high…considering the age of these subjects”.21
At this point, a total of 34
subjects were randomly divided into two groups. One group
continued with the amended diet, while a second group continued
the diet while also taking 500 IU of GliSODin® daily. Subjects’
progress was then monitored for two additional years. During
this phase, parameters such as blood pressure, BMI, and LDL
levels remained largely unchanged among all subjects. But about
nine months after beginning GliSODin® treatment, significant
improvements in antioxidant status were documented in the
treatment group. Antioxidants monitored included blood SOD
levels and blood glutathione peroxidase levels. Levels of
malondialdehyde (a biomarker for oxidative stress24)
were also documented. The antioxidant status of control
subjects, who were not taking the supplement, remained
essentially unchanged.
Atherosclerosis is
Reversed
About a year and a half after
commencing daily supplementation with GliSODin®, measurable
decreases in subjects’ IMT were detected. Approximately two
years after starting GliSODin® supplementation, decreases in IMT
values became statistically significant. In dramatic contrast,
control subjects not receiving GliSODin® experienced increased
IMT values over the same period.21
There were no reported side effects in either group.
This remarkable study demonstrated
that reversal of atherosclerosis in adults with multiple risk
factors for future cardiovascular disease is possible through a
combination of healthy diet and daily intake of GliSODin®
(orally bioavailable superoxide dismutase). These findings were
confirmed by monitoring of clinical and biological health
parameters, and measurements of carotid IMT. The GliSODin®
regimen, “improves, significantly, the anti-oxidant status,”
noted investigators, “and diminishes, remarkably, carotid
artery IMT.”21
It should be noted that these
findings echo those of other researchers, who, in previous and
subsequent studies, have convincingly demonstrated GliSODin®’s
ability to reduce oxidative damage in human volunteers and
animal models.25-27
Pomegranate Fights Oxidative
Damage, Reverses Atherosclerosis
Scientists have recently shown
that pomegranate juice offers cardiac health benefits that
complement those of GliSODin®. In the past seven years alone,
the amount of published research on pomegranate has increased
seven-fold over all preceding years in the medical and
scientific literature.40
That’s almost certainly because each new study underscores the
potential of this fruit to fight cancer and to combat oxidative
stress. The latter is of particular importance for
atherosclerosis prevention.
In 2004, researchers published the
findings of a three-year study on the daily consumption of
pomegranate juice (50 mL, or 1.7 ounces) by patients with
advanced atherosclerosis.41
These patients were diagnosed with carotid artery stenosis; a
serious condition in which the carotid arteries, responsible for
supplying blood to the brain, become noticeably narrowed by
buildup of atherosclerotic plaques. Such patients are at
increased risk of suffering strokes or other “cerebrovascular
accidents”. In this study, common carotid IMT increased
by 9% within one year in the
non-supplemented control group. Remarkably, patients drinking
pomegranate juice experienced a whopping 35% reduction in the
IMT score and a 44% improvement in carotid artery blood flow
over the same period. Investigators also documented a 21%
reduction in systolic blood pressure among the pomegranate juice
drinkers. Serum total antioxidant status was increased by an
extraordinary 130% after one year of pomegranate
supplementation. Additionally, the scientists monitored the
status of an enzyme that may protect against the development of
atherosclerotic plaque by protecting LDL against oxidative
modification. Pomegranate drinkers’ levels of this beneficial
enzyme increased by 83% after just one year. “For all studied
parameters, the maximal effects were observed after one year of
consumption,” wrote the researchers.41
Other researchers from around the
globe have obtained similar results when studying pomegranate’s
ability to rapidly improve volunteers’ antioxidant status,42
to reduce oxidative stress, and to reverse processes that
contribute to the promotion and progression of atherosclerosis,
including coronary artery narrowing and LDL oxidation.43-47
Conclusion
Atherosclerosis is a serious
threat to health. Its progression has been linked to increased
risk of heart attack, stroke, atrial fibrillation and dementia,
among other potentially fatal conditions. Since it may begin as
early as childhood, and aging has been identified as the
greatest risk factor for its development, it is vital to combat
this arterial-dysfunction disease as early—and as
aggressively—as possible. Nature has provided the means to
protect ourselves from this insidious threat. By increasing our
levels of the natural enzymatic antioxidant, superoxide
dismutase (SOD), and by harnessing the potent polyphenol power
of pomegranate, scientists have shown that it is now possible to
help reverse the course of atherosclerosis—naturally.
References
1. Osika W,
Dangardt F, Gronros J, et al. Increasing peripheral artery
intima thickness from childhood to seniority. Arterioscler
Thromb Vasc Biol. 2007 Mar;27(3):671-6.
2. Wei EP,
Kontos HA, Christman CW, DeWitt DS. Superoxide generation and
reversal of acetylcholine-induced cerebral arteriolar dilation
after acute hypertension. Circ Res. 1985;57:781–7.
3. Rubanyi
GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate
endothelium-derived relaxing factor. Am J Physiol Heart Circ
Physiol. 1986; 250: H822–7.
4. Hathaway
C, Heistad DD, Piegors DJ, Miller FM. Regression of
atherosclerosis in monkeys reduces vascular superoxide levels.
Circ Res. 2002;90:277–83.
5. Wilcox
CS. Oxidative stress and nitric oxide deficiency in the kidney:
A critical link to hypertension? Am J Physiol Reg. 2005; 289:
R913–35.
6. Lund DD,
Faraci FM, Miller FJ Jr., Heistad DD. Gene transfer of
endothelial nitric oxide synthase improves relaxation of carotid
arteries from diabetic rabbits. Circulation. 2000;101:1027–33.
7.
Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G.
Endothelial dysfunction in chronic myocardial infarction despite
increased vascular endothelial nitric oxide synthase and soluble
guanylate cyclase expression: role of enhanced vascular
superoxide production. Circulation. 1999;100:292–8.
8.
Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidant
stress and endothelial dysfunction in patients with chronic
heart failure: role of xanthine-oxidase and extracellular
superoxide dismutase. Circulation. 2002;106:3073–8.
9.
Kotur-Stevuljevic J, Memon L, Stefanovic A, et al. Correlation
of oxidative stress parameters and inflammatory markers in
coronary artery disease patients. Clin Biochem. 2007
Feb;40(3-4):181-7.
10. Heistad
DD. Oxidative stress and vascular disease: 2005 Duff lecture.
Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):689-95.
11.
Vicenzini E, Ricciardi MC, Puccinelli F, et al. Common carotid
artery intima-media thickness determinants in a population
study. J Ultrasound Med. 2007Apr;26(4):427-32.
12.
Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines
and disease. Immunol Allergy Clin North Am. 2003
Feb;23(1):15-39.
13. Krabbe
KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the
elderly. Exp Gerontol. 2004 May;39(5):687-99.
14. Payne GW.
Effect of inflammation on the aging microcirculation: impact on
skeletal muscle blood flow control. Microcirculation. 2006
Jun;13(4):343-52.
15. Faloon
W. How much fish oil is in your blood? Life Extension. Jun
2007;13(6):6-9.
16. de Groot
E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode
ultrasound assessment of pravastatin treatment effect on carotid
and femoral artery walls and its correlations with coronary
arteriographic findings: a report of the Regression Growth
Evaluation Statin Study (REGRESS). Am Coll Cardiol. 1998
Jun;31(7):1561-7.
17. Salonen
R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis
Prevention Study (KAPS). A population-based primary preventive
trial of the effect of LDL lowering on atherosclerotic
progression in carotid and femoral arteries. Circulation. 1995
Oct 1;92(7):1758-64.
18. Nissen
SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity
statin therapy on regression of coronary atherosclerosis: the
ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65.
19. Taylor
AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN.
ARBITER: Arterial Biology for the Investigation of the Treatment
Effects of Reducing Cholesterol: a randomized trial comparing
the effects of atorvastatin and pravastatin on carotid intima
medial thickness. Circulation. 2002 Oct 15;106(16):2055-60.
20. Crouse
JR, III, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on
progression of carotid intima-media thickness in low-risk
individuals with subclinical atherosclerosis: the METEOR Trial.
JAMA. 2007 Mar 28;297(12):1344-53.
21. Cloarec
M, Caillard P, Provost JC, et al. GliSODin, a vegetal sod with
gliadin, as preventative agent vs. atherosclerosis, as confirmed
with carotid ultrasound-B imaging. Allerg Immunol.(Paris). 2007
Feb;39(2):45-50.
22.
Vouldoukis I, Conti M, Krauss P, et al. Supplementation with
gliadin-combined plant superoxide dismutase extract promotes
antioxidant defences and protects against oxidative stress.
Phytother Res. 2004 Dec;18(12):957-62.
23. Dugas B.
Glisodin®, a nutraceutical product that promotes the oral
delivery of superoxide dismutase. Free Radic Biol Med.
2002;33:S64.
24. Nielsen
F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma
malondialdehyde as biomarker for oxidative stress: reference
interval and effects of life-style factors. Clin Chem. 1997
Jul;43(7):1209-14.
25. Kick J,
Hauser B, Bracht H, et al. Effects of a cantaloupe melon
extract/wheat gliadin biopolymer during aortic cross-clamping.
Intensive Care Med. 2007 Apr;33(4):694-702.
26. Muth CM,
Glenz Y, Klaus M, et al. Influence of an orally effective SOD on
hyperbaric oxygen-related cell damage. Free Radic Res. 2004
Sep;38(9):927-32.
27. Naito Y,
Akagiri S, Uchiyama K, et al. Reduction of diabetes-induced
renal oxidative stress by a cantaloupe melon extract/gliadin
biopolymers, oxykine, in mice. Biofactors. 2005;23(2):85-95.
28. van OM,
Jan de JF, Witteman JC, et al. Atherosclerosis and risk for
dementia. Ann Neurol. 2007 Feb 27.
29. Muller
M, Grobbee DE, Aleman A, Bots M, van der Schouw YT.
Cardiovascular disease and cognitive performance in middle-aged
and elderly men. Atherosclerosis. 2007 Jan;190(1):143-9.
30. Vaudo G,
Marchesi S, Siepi D, et al. Metabolic syndrome and preclinical
atherosclerosis: focus on femoral arteries. Metabolism. 2007
Apr;56(4):541-6.
31. Heeringa
J, van der Kuip DA, Hofman A, et al. Subclinical atherosclerosis
and risk of atrial fibrillation: the rotterdam study. Arch
Intern Med. 2007 Feb 26;167(4):382-7
32. Lekakis
JP, Papamichael C, Papaioannou TG, et al. Intima-media thickness
score from carotid and femoral arteries predicts the extent of
coronary artery disease: intima-media thickness and CAD. Int J
Cardiovasc Imaging. 2005 Oct;21(5):495-501.
33. Salonen
R, Haapanen A, Salonen JT. Measurement of intima-media thickness
of common carotid arteries with high-resolution B-mode
ultrasonography: inter- and intra-observer variability.
Ultrasound Med Biol. 1991;17(3):225-30.
34. Girerd
X, Mourad JJ, Acar C, et al. Noninvasive measurement of
medium-sized artery intima-media thickness in humans: in vitro
validation. J Vasc Res. 1994 Mar;31(2):114-20.
35. Nathan
DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and
carotid intima-media thickness in type 1 diabetes mellitus. N
Engl J Med. 2003 Jun 5;348(23):2294-303.
36. Soroka
NN, Ryzhak GA. Ultrasonic diagnostics of mediointimal
hyperplasia as a predictor of atherosclerosis in old people. Adv
Gerontol. 2006;19:102-6.
37.
Abdelghaffar S, El AM, El HA, El MF. Carotid intima-media
thickness: an index for subclinical atherosclerosis in type 1
diabetes. J Trop Pediatr. 2006 Feb;52(1):39-45.
38. O’Leary
DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media
thickness as a risk factor for myocardial infarction and stroke
in older adults. Cardiovascular Health Study Collaborative
Research Group. N Engl J Med. 1999 Jan 7;340(1):14-22.
39. Hodis HN,
Mack WJ, LaBree L, et al. The role of carotid arterial intima-media
thickness in predicting clinical coronary events. Ann Intern
Med. 1998 Feb 15;128(4):262-9.
40. Lansky
EP, Newman RA. Punica granatum (pomegranate) and its potential
for prevention and treatment of inflammation and cancer. J
Ethnopharmacol. 2007 Jan 19;109(2):177-206.
41. Aviram
M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption
for 3 years by patients with carotid artery stenosis reduces
common carotid intima-media thickness, blood pressure and LDL
oxidation. Clin Nutr. 2004 Jun;23(3):423-33.
42.
Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L,
Derendorf H. Absorption, metabolism, and antioxidant effects of
pomegranate (Punica granatum l.) polyphenols after ingestion of
a standardized extract in healthy human volunteers. J Agric Food
Chem. 2006 Nov 15;54(23):8956-61.
43. de NF,
Williams-Ignarro S, Sica V, et al. Effects of a pomegranate
fruit extract rich in punicalagin on oxidation-sensitive genes
and eNOS activity at sites of perturbed shear stress and
atherogenesis. Cardiovasc Res. 2007 Jan 15;73(2):414-423.
44.
Rosenblat M, Hayek T, Aviram M. Anti-oxidative effects of
pomegranate juice (PJ) consumption by diabetic patients on serum
and on macrophages. Atherosclerosis. 2006 Aug;187(2):363-371.
45. Kaplan
M, Hayek T, Raz A, et al. Pomegranate juice supplementation to
atherosclerotic mice reduces macrophage lipid peroxidation,
cellular cholesterol accumulation and development of
atherosclerosis. J Nutr. 2001 Aug;131(8):2082-9.
46. Fuhrman
B, Volkova N, Aviram M. Pomegranate juice inhibits oxidized LDL
uptake and cholesterol biosynthesis in macrophages. J Nutr
Biochem. 2005 Sep;16(9):570-6.
47. Tuttle
D. Pomegranate reverses atherosclerosis and slows the
progression of prostate cancer. Life Extension. Feb
2007;13(2):72-7.
|
|
 |
|